May 17, 2022Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross ProfitCosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022 Reports Positive Net Income of $0.2 Million and $1.2 Million of EBITDA for the First Quarter of 2022 CHICAGO, IL / ACCESSWIRE / May 18, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
Cosmos Holdings Reports 12.5% Increase in Revenue, 88.9% Increase in Gross Profit and Achieves Profitability for the First Quarter of 2022 Reports Positive Net Income of $0.2 Million and $1.2 Million of EBITDA for the First Quarter of 2022 CHICAGO, IL / ACCESSWIRE / May 18, 2022 / Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
